Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Lymphoid 2Dermatologic 2

Conditions

Hodgkin Disease 77Lymphoma 34Lymphoma, Large-Cell, Anaplastic 24Hematologic Diseases 20Recurrence 16Lymphoma, Non-Hodgkin 16Lymphoma, T-Cell 13Lymphoma, T-Cell, Peripheral 12Lymphoma, T-Cell, Cutaneous 12Lymphoma, Large B-Cell, Diffuse 10Mycosis Fungoides 9Sezary Syndrome 5Neoplasms 5Lymphoma, B-Cell 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphomatoid Papulosis 4Lymphoma, Primary Cutaneous Anaplastic Large Cell 4Lymphatic Diseases 4Leukemia, Myeloid, Acute 4Immunoblastic Lymphadenopathy 4Enteropathy-Associated T-Cell Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms, Germ Cell and Embryonal 3Lymphoma, Follicular 3Leukemia 3Dendritic Cell Sarcoma, Interdigitating 3Testicular Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2

Interventions

Cyclophosphamide 76fludarabine phosphate 41Filgrastim 38Peripheral Blood Stem Cell Transplantation 34Radiotherapy 33Cyclosporine 32Busulfan 31Etoposide 30Mycophenolic Acid 29Antilymphocyte Serum 28Whole-Body Irradiation 25Methotrexate 25Rituximab 22Melphalan 21Methylprednisolone 20Vincristine 17Tacrolimus 16Doxorubicin 16Cytarabine 16Cord Blood Stem Cell Transplantation 16Prednisone 15Thiotepa 10Granulocyte Colony-Stimulating Factor 9Carboplatin 8Leucovorin 7fludarabine 6aldesleukin 6Ifosfamide 6sargramostim 5Sirolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Dendritic Cell Sarcoma, Interdigitating × Brentuximab Vedotin × Clear all
NCT06186986 2024-01-02

CD30 Imaging in Diffuse Large B-cell Lymphoma

University Medical Center Groningen

Phase 3 Unknown
20 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT00099255 2014-12-18

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

Seagen Inc.

Phase 2 Completed
40 enrolled
DermatologicLymphoidSarcoma

Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Dendritic Cell Sarcoma, Interdigitating

NCT00051597 2011-10-12

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Seagen Inc.

Phase 1/2 Completed
70 enrolled
DermatologicLymphoidSarcoma

Hodgkin Disease, Sarcoma, Kaposi, Lymphoma, B-Cell, Lymphoma, T-Cell, Cutaneous, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡